2026 RISE UP Conference Targets Breast Cancer and Women9s Health Advances
The trial demonstrates that communicating individualized breast cancer risk can be safely used to modify screening intervals and that doing so may improve both clinical outcomes and psychological well‑being.
The 2026 RISE UP for Breast Cancer and Women9s Health Conference presented early results from the PRSONAL randomized clinical trial. The study evaluated whether individualized breast cancer risk calculated with the CanRisk model could safely determine screening intervals and whether communicating that risk had psychological benefits. Women aged 50‑67 were randomized to continued standard biennial screening or to risk-based screening where ten‑year absolute risk was computed and communicated automatically. The trial assessed clinical outcomes (detection, recall, interval cancers) and psychological impact (distress, acceptance of de‑escalated screening). Findings demonstrate that a risk‑stratified approach can be embedded into routine national programs and have implications for tailoring screening frequency to individual risk, potentially improving benefit‑to‑harm ratios.
Traditional uniform mammography screening often over‑treats low‑risk women and under‑treats high‑risk women. Evidence that risk‑based screening is feasible and psychologically acceptable supports a shift toward personalized screening schedules, which could enhance mortality benefits while reducing unnecessary procedures and anxiety.
Bizonyítékszint: Állatkísérletes. Állatmodellben vizsgálták.
Kapcsolódó jelek
- 20‑Year Risks of Breast‑Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- Breast Cancer: The good, the bad, and an important call to effective risk reduction strategies
- Clinical Trials in Cancer - Transforming Clinical Research in the United States - NCBI Bookshelf
- Decoding Clinical Trials in Metastatic Breast Cancer: Practical Insights for Optimal Therapy Sequencing
- The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21st century: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivors - PMC